DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of best-in-class small molecule inhibitors and agonists of the cGAS-STING pathway to address indications in inflammation, autoimmunity and oncology, announced the appointment of Thomas W.

达拉斯，2024年5月1日（环球通讯社）--Immunsensor Therapeutics是一家临床阶段生物治疗公司，专注于开发cGAS-STING途径的同类最佳小分子抑制剂和激动剂，以解决炎症，自身免疫和肿瘤学的适应症，宣布任命Thomas W。

Dubensky, Jr., Ph.D., as president and chief executive officer and a member of the Board of Directors, effective immediately..

Dubensky，Jr.，博士，总裁兼首席执行官兼董事会成员，立即生效。。

Dr. Dubensky is a veteran biopharma executive and entrepreneur with a track record of strategic leadership in both private and public companies. He brings significant expertise in the discovery, development and translation of novel small molecule-, biologic- and vector-based therapies, having led teams advancing several first-in-human drug candidates.

杜本斯基博士是一位经验丰富的生物制药高管和企业家，在私营和上市公司都有战略领导的记录。他在新型小分子，生物和载体疗法的发现，开发和翻译方面带来了重要的专业知识，领导团队推进了几项人类候选药物的首次开发。

Most recently, Dr. Dubensky was the founding CEO of Tempest Therapeutics, joining the company in 2017. Earlier in his career, he held roles leading discovery biology, development and clinical translation in cancer immunotherapy and infectious disease indications at multiple biotech companies, including, Viagene, Chiron, Onyx, Cerus, Immune Design and Aduro.

最近，Dubensky博士是Tempest Therapeutics的创始首席执行官，于2017年加入该公司。在职业生涯早期，他曾在多家生物技术公司（包括Viagene、Chiron、Onyx、Cerus、Immune Design和Aduro）担任癌症免疫治疗和传染病适应症的发现生物学、开发和临床翻译领导。

He has an extensive publication and patent record, including work on the biology and the development of small molecule drugs targeting the cGAS-STING signaling pathway in cancer and immunity..

他拥有广泛的出版物和专利记录，包括生物学方面的工作以及针对癌症和免疫中cGAS-STING信号通路的小分子药物的开发。。

Dr. Dubensky received his B.A. in Bacteriology and Immunology from the University of California, Berkeley, his Ph.D. at the University of Colorado Health Sciences Center, conducted his post-doctoral studies at Harvard Medical School in the Department of Pathology and received executive training at the University of California, San Diego, Executive Program for Scientists and Engineers..

Dubensky博士在加州大学伯克利分校获得了细菌学和免疫学学士学位，在科罗拉多大学健康科学中心获得了博士学位，在哈佛医学院病理学系进行了博士后研究，并在加利福尼亚大学圣地亚哥分校接受了科学家和工程师执行计划的执行培训。。

ImmuneSensor Therapeutics was founded through licensing of technologies developed in the laboratory of Dr. Zhijian ‘James’ Chen at the University of Texas Southwestern Medical School. Dr. Chen’s laboratory discovered the cellular enzyme cGAS (cyclic GMP-AMP synthase) and its product cGAMP (cyclic GMP-AMP), which in turn activates STING (Stimulator of Interferon Genes), leading to the production of type-I interferons and other cytokines that can shape an effective adaptive immune response but can also cause pathologic inflammation and autoimmunity.

Immunsensor Therapeutics是通过德克萨斯大学西南医学院陈志坚博士实验室开发的技术许可成立的。陈博士的实验室发现了细胞酶cGAS（环状GMP-AMP合酶）及其产物cGAMP（环状GMP-AMP），它反过来激活STING（干扰素基因的刺激物），导致产生I型干扰素和其他细胞因子，这些细胞因子可以形成有效的适应性免疫反应，但也可以引起病理性炎症和自身免疫。

Dr. Chen, also an Investigator of Howard Hughes Medical Institute and a member of the National Academies of Sciences and Medicine, is a recipient of multiple awards for his fundamental discoveries of the cGAS-STING pathway, including the 2019 Breakthrough Prize in Life Sciences..

陈博士也是霍华德·休斯医学研究所（Howard Hughes Medical Institute）的研究员，也是美国国家科学与医学院（National Academy of Sciences and Medicine）的成员，因其对cGAS-STING途径的基本发现而获得多项奖项，包括2019年生命科学突破奖。。

“I believe that ImmuneSensor’s technology and capabilities provide unparalleled ability to drug and realize the broad therapeutic potential of targeting the cGAS-STING pathway to develop novel medicines to address diverse, significant inflammatory and autoimmune diseases, and cancer,” said Dr. Dubensky.

Dubensky博士说：“我相信Immunsensor的技术和能力提供了无与伦比的药物治疗能力，并实现了靶向cGAS-STING途径的广泛治疗潜力，以开发针对多种重要炎症和自身免疫性疾病以及癌症的新药。”。

“I am excited to have the opportunity to lead the talented ImmuneSensor team and to work with Dr. Chen as we expand and advance the company’s proprietary small molecule pipeline of novel cGAS inhibitors in inflammatory conditions as well as the ongoing randomized Phase 2 clinical trial of our STING agonist in solid tumors.”.

“我很高兴有机会领导才华横溢的免疫传感器团队，并与陈博士合作，扩大和推进公司专有的新型cGAS抑制剂在炎症条件下的小分子管道，以及正在进行的STING激动剂在实体瘤中的随机2期临床试验。”。

Mr. Jet Li, co-founder, chairman of the Board of Directors and former CEO noted, “Tom brings significant scientific and leadership experience in drug development, and we are delighted to welcome him as CEO. We look forward to working with Tom to advance therapies that have the potential to address patients’ unmet medical needs in diverse therapeutic areas.”.

联合创始人、董事会主席、前首席执行官李连杰先生指出：“汤姆在药物开发方面带来了丰富的科学和领导经验，我们很高兴欢迎他担任首席执行官。我们期待着与汤姆合作，推进有可能解决患者在不同治疗领域未满足的医疗需求的疗法。”。

Pioneering the Development of Modulators of the cGAS-STING Pathway

开创cGAS-STING途径调节剂的开发

The detection of cytoplasmic DNA plays a critical role in immunity, provoking a complex immune cascade that works to protect the body. One of the key pathways in this powerful innate immune system is the cGAS-STING pathway, which works to detect both foreign and host-derived cytoplasmic DNA produced as a result of infection or cell damage due to malignancy or inflammation.

细胞质DNA的检测在免疫中起着至关重要的作用，引发了一个复杂的免疫级联反应，可以保护身体。这种强大的先天免疫系统的关键途径之一是cGAS-STING途径，它可以检测由于恶性肿瘤或炎症引起的感染或细胞损伤而产生的外源和宿主来源的细胞质DNA。

The cGAS-STING signaling pathway provides important therapeutic targets for the potential treatment of autoimmunity, inflammation and cancer..

cGAS-STING信号通路为自身免疫，炎症和癌症的潜在治疗提供了重要的治疗靶点。。

In autoimmune diseases, the innate immune response is overactive and lacks the ability to distinguish between its own cells and foreign cells resulting in aberrant attacking of normal cells. ImmuneSensor’s inhibitor molecules are being designed to inhibit the cGAS-STING pathway to reinstate immune homeostasis.

在自身免疫性疾病中，先天免疫反应过度活跃，缺乏区分自身细胞和外来细胞的能力，导致正常细胞的异常攻击。免疫传感器的抑制剂分子被设计用于抑制cGAS-STING途径以恢复免疫稳态。

ImmuneSensor is preparing to advance its orally available small molecule cGAS inhibitor, IMSB-301, in a study in healthy volunteers in 2024. The results from this Phase 1 trial will position the Company to evaluate IMSB-301 in Phase 2 studies across diverse therapeutic areas, such as Type-I interferonopathies, diabetic kidney diseases, age-related macular degeneration, and eventually other autoimmune disorders and neurodegenerative diseases..

免疫传感器（Immunsensor）正准备在2024年对健康志愿者进行的一项研究中，改进其口服小分子cGAS抑制剂IMSB-301。第一阶段试验的结果将使该公司能够在不同治疗领域的第二阶段研究中评估IMSB-301，例如I型干扰素病，糖尿病肾病，年龄相关性黄斑变性，以及最终其他自身免疫性疾病和神经退行性疾病。。

In cancer, the cGAS-STING pathway, once activated and engaged, can stimulate endogenous antitumor immunity. ImmuneSensor’s lead clinical asset, IMSA101, is a novel small molecule STING agonist designed with a unique “defense-sensing” mechanism that increases antitumor immunity and stimulates cytokines to turn “cold” tumors to “hot”.

在癌症中，cGAS-STING途径一旦被激活并参与，就可以刺激内源性抗肿瘤免疫。Immunsensor的主要临床资产IMSA101是一种新型小分子STING激动剂，其设计具有独特的“防御感应”机制，可增强抗肿瘤免疫力并刺激细胞因子将“冷”肿瘤变为“热”。

Extending completed Phase 1 monotherapy and immune checkpoint inhibitor combination studies, the company is currently evaluating IMSA101 in combination with radiation and checkpoint inhibitors in two proof of concept Phase 2 clinical trials in patients with solid tumor malignancies (NCT05846659, NCT05846646).

扩展已完成的1期单一疗法和免疫检查点抑制剂联合研究，该公司目前正在评估IMSA101与放射和检查点抑制剂联合用于实体瘤恶性肿瘤患者的两项概念验证2期临床试验（NCT05846659，NCT05846646）。

ImmuneSensor is the first company to advance a novel STING agonist to a randomized Phase 2 clinical study..

Immunsensor是第一家将新型STING激动剂推进随机2期临床研究的公司。。

About ImmuneSensor Therapeutics

关于免疫传感器疗法

ImmuneSensor is a privately held, clinical stage company developing best-in-class small molecule inhibitors and agonists of the cGAS-STING signaling pathway to potentially address therapeutic areas with significant unmet medical need in autoimmunity, inflammation and oncology. For more information about ImmuneSensor, visit: www.immunesensor.com.

Immunsensor是一家私营的临床阶段公司，开发cGAS-STING信号通路的同类最佳小分子抑制剂和激动剂，以潜在地解决自身免疫，炎症和肿瘤学中未满足医疗需求的治疗领域。有关免疫传感器的更多信息，请访问：www.ImmuneSensor.com。

Contacts:

联系人：

Investors

投资者

Elizabeth Wolffe, Ph.D.

伊丽莎白·沃尔夫博士。

Wheelhouse Life Science Advisors

驾驶室生命科学顾问

lwolffe@wheelhouselsa.com

lwolffe@wheelhouselsa.com

Media

媒体

Aljanae Reynolds

Aljanae Reynolds

Wheelhouse Life Science Advisors

驾驶室生命科学顾问

areynolds@wheelhouselsa.com

areynolds@wheelhouselsa.com